Copyright
©The Author(s) 2022.
World J Gastroenterol. Dec 21, 2022; 28(47): 6619-6631
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6619
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6619
Table 2 Cost-effectiveness studies, endoscopic therapy vs surgery
Ref. | Year | Country | Endoscopic technique | Design | Comparison | Costs analyzed | Results |
Swan et al[19] | 2009 | Australia | EMR | Observational monocentric | Endoscopy vs surgery, Considering surgery without major complications | Direct costs including a 1-day hospital stay for EMR, Loss of utility not considered | EAC: $2051 pp, SAC: $9041 |
Jayanna et al[16] | 2016 | Australia | EMR | Observational multicentric | Endoscopy vs surgery, Considering surgery with and without complications | Direct costs including hospital stay and adverse events, 1st surveillance endoscopy | EAC: $4668 pp, SAC: $12720, If surgery 7.5% complications -> SAC: $45530 |
Law et al[17] | 2016 | USA | EMR | Decision analysis tree (hybrid Markov model) | Endoscopy (resection + surveillance, surgery if recurrence at 12 mo) vs laparoscopic surgery, Considering complications in both arms | Direct costs, Loss of utility considered, QALY, Sensitivity analysis | EAC: $5570 ppEndoscopy QALY: 9.64, SAC: $18717 pp, Surgery QALY: 9.58, Laparoscopy is cost-effective if complete EMR < 75.8%, EMR adverse events rate > 12% and laparoscopy cost < $14.000 |
Dahan et al[18] | 2019 | France | ESD | Observational monocentric | Endoscopy vs surgery, Considering complications in both arms | Direct costs including hospital stay and endoscopy costs | EAC: €3190, SAC: €8490 |
Buskermolen et al[13] | 2022 | Netherlands | Non-specified | Microsimulation screening analysis (MISCAN-colon) | Surgery vs attempted removal by an expert endoscopist, Considering complications in both arms | Direct costs, Loss of utility considered, QALY, Sensitivity analysis | EAC: €60.200, SAC: €72.700, Endoscopy QALY: 33.1/1000 individuals, Surgery QALY: 32.9/1000 individuals |
- Citation: Bustamante-Balén M. How to avoid overtreatment of benign colorectal lesions: Rationale for an evidence-based management. World J Gastroenterol 2022; 28(47): 6619-6631
- URL: https://www.wjgnet.com/1007-9327/full/v28/i47/6619.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i47.6619